Retrospective Evaluation of the Role of Gemcitabine-Docetaxel in Well-Differentiated and Dedifferentiated Liposarcoma

Authors

Prapassorn Thirasastr
Heather Lin
Behrang Amini
Wei-Lien Wang
Jeffrey M Cloutier
Elise F Nassif
Emily Z Keung
Christina L Roland
Barry Feig
Dejka Araujo
Robert S Benjamin
Anthony P Conley
John A Livingston
Joseph Ludwig
Shreyaskumar Patel
Ravin Ratan
Vinod Ravi
Maria Alejandra Zarzour
Xiao Zhou
Neeta Somaiah

Publication Date

2-1-2023

Journal

Cancer Medicine

Abstract

OBJECTIVE: Well-differentiated (WDLPS) and dedifferentiated liposarcoma (DDLPS) account for the majority of liposarcomas. Although gemcitabine-docetaxel is used as second-line treatment in soft tissue sarcomas, its efficacy in WDLPS/DDLPS is not established. This study retrospectively analyzed the efficacy of gemcitabine regimens in WDLPS/DDLPS.

METHODS: All patients with WDLPS or DDLPS who received gemcitabine-based chemotherapy at our institution between September 2002 and January 2021 were included. Response was evaluated by an independent radiologist using RECIST 1.1. The Kaplan-Meier method was used to estimate distributions of survival outcomes and log-rank tests were used to compare survival outcomes between subgroups.

RESULTS: Sixty-five WDLPS/DDLPS patients were included. Seven patients (10.8%) received a gemcitabine-based regimen more than once, totaling 72 treatments. The median age at the start of treatment was 66 years (range 32-80 years). Sixty-five (90.3%) regimens were gemcitabine-docetaxel, and 7 (9.7%) were gemcitabine alone. Majorities of treatments were for disease that was recurrent/metastatic (86.1%), was abdominal/retroperitoneal (83.3%), and had DDLPS components (88.9%), while 25.0% of treatments were for multifocal disease. The overall response rate was 9.7% (7/72). All responses were in patients with documented DDLPS. The median time to progression was 9.2 months (95% CI 5.3-12.3 months). The median overall survival from the start of therapy was 18.8 months (95% CI 13.1-32.4 months).

CONCLUSION: Gemcitabine-docetaxel is an efficacious second-line treatment for DDLPS. Though cross study comparisons are not advisable, response to gemcitabine-docetaxel compares favorably to current standard options trabectedin and eribulin. This combination is a valid comparator arm for future second-line trials in DDLPS.

Keywords

Humans, Adult, Middle Aged, Aged, Aged, 80 and over, Docetaxel, Gemcitabine, Retrospective Studies, Trabectedin, Liposarcoma

Comments

Supplementary Materials

Data Availability Statement

PMID: 36151848